A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
← catalyst calendarSponsored by H. Lundbeck A/S (industry) · HLUN-B.CO — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
164actual
Sites
28
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-18 | actual | When the study began enrolling |
| Primary completion | 2026-06-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-05 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Intervention
- Drug: Eptinezumab
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Response of "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGIC) Scale
measured Week 24
Permalink · HLUN-B.CO's whole pipeline · Catalyst calendar · Every registered study · What changed